Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Day One Biopharmaceuticals ( (DAWN) ) just unveiled an update.
On August 5, 2025, Day One Biopharmaceuticals reported its second quarter 2025 financial results, highlighting a strong performance with OJEMDA net product revenue reaching $33.6 million, marking a 310% increase from the previous year. The company also announced ongoing progress in its clinical trials, including the Phase 1a/b trial of DAY301 and the FIREFLY-1 and FIREFLY-2 trials, while ending a collaboration with Sprint Bioscience AB. With a solid cash position of $453.1 million, Day One aims to continue its momentum by focusing on revenue growth, pipeline advancement, and strategic portfolio expansion.
The most recent analyst rating on (DAWN) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Day One Biopharmaceuticals stock, see the DAWN Stock Forecast page.
Spark’s Take on DAWN Stock
According to Spark, TipRanks’ AI Analyst, DAWN is a Neutral.
Day One Biopharmaceuticals shows strong growth potential, particularly with the success of OJEMDA and a solid cash position. However, consistent net losses, negative technical indicators, and a challenging valuation due to ongoing losses present significant risks. The strong momentum from recent earnings highlights provides some optimism, balancing out the weaker financial and technical aspects.
To see Spark’s full report on DAWN stock, click here.
More about Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biopharmaceutical company focused on developing and commercializing targeted therapies for life-threatening diseases, particularly in pediatric cancer. The company collaborates with clinical oncologists, families, and scientists to develop important cancer treatments, with a pipeline that includes tovorafenib (OJEMDA) and DAY301.
Average Trading Volume: 1,405,250
Technical Sentiment Signal: Sell
Current Market Cap: $674.1M
See more insights into DAWN stock on TipRanks’ Stock Analysis page.